Literature DB >> 9354443

Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.

A Gabr1, A Kuin, M Aalders, H El-Gawly, L A Smets.   

Abstract

pH-mediated conversions in the structure of the topoisomerase (topo) I inhibitors camptothecin (CPT) and its analogues have strong implications for the pharmacokinetics and pharmacodynamics of these novel anticancer agents. Because the cell-penetrating and biologically active lactone isomers predominate at acidic conditions, we have tested if low pH potentiates the cytotoxic and antitumor effects of CPT and its water-soluble derivative topotecan (TPT). In L1210 leukemia cells, rapid initial uptake of radiolabeled CPT and TPT was followed by a gradual release from cells at physiological pH 7.4, whereas high drug levels were maintained in cells at pH 6.2. Steady-state uptake levels of CPT increased proportionally, up to 5-fold, with decreasing pH of the incubating medium (from 7.4 to 6.0). With TPT, a maximum 3-fold increase was observed at pH 6.8 to 6.4. By contrast, the cellular pharmacokinetics of the topoisomerase II inhibitor etoposide (ETP) were independent of the ambient pH. The large increases in intracellular CPT and TPT levels caused only moderate potentiation of cytotoxicity in short-term incubations. Conditions of very low pH < or =6.2 even antagonized the cytotoxicity of the topo I and topo II inhibitors, due to inhibition of DNA synthesis by intracellular acidification. However, in clinically relevant schedules of prolonged exposures at low drug concentration, low pH potentiated the cytotoxicity of CPT and TPT by 2-3-fold. To investigate the effect of local pH in vivo, the basal interstitial pH of 6.8 of RIF-1 tumors was selectively lowered by i.p. injection of the host animals with the mitochondrial inhibitor meta-iodobenzylguanidine (32 mg/kg) and glucose (1.5 g/kg). In accordance with the pH optimum for TPT uptake at pH 6.8 to 6.4, tumor acidification had no effect on the antitumor effect of this analogue. By contrast, the intervention significantly potentiated the response of tumors to CPT. The results indicate that local pH is an important determinant of the cellular pharmacokinetics and the antitumor activity of CPT and analogues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354443

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  C-lysine conjugates: pH-controlled light-activated reagents for efficient double-stranded DNA cleavage with implications for cancer therapy.

Authors:  Wang-Yong Yang; Boris Breiner; Serguei V Kovalenko; Chi Ben; Mani Singh; Shauna N LeGrand; Qing-Xiang Amy Sang; Geoffrey F Strouse; John A Copland; Igor V Alabugin
Journal:  J Am Chem Soc       Date:  2009-08-19       Impact factor: 15.419

2.  BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.

Authors:  David J Adams; William R Waud; Mansukh C Wani; Govindarajan Manikumar; James L Flowers; Timothy A Driscoll; Lee Roy Morgan
Journal:  Cancer Chemother Pharmacol       Date:  2010-06-22       Impact factor: 3.333

Review 3.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

4.  Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

Authors:  G P Feeney; R J Errington; M Wiltshire; N Marquez; S C Chappell; P J Smith
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

5.  Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

Authors:  Feng An; Daryl C Drummond; Shannon Wilson; Dmitri B Kirpotin; Stephen L Nishimura; V Courtney Broaddus; Bin Liu
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

Review 6.  Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

Authors:  Vincent J Venditto; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

7.  Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Authors:  A Kuin; M Aalders; M Lamfers; D J van Zuidam; M Essers; J H Beijnen; L A Smets
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  Honokiol-camptothecin loaded graphene oxide nanoparticle towards combinatorial anti-cancer drug delivery.

Authors:  Ananya Deb; Nirmala Grace Andrews; Vimala Raghavan
Journal:  IET Nanobiotechnol       Date:  2020-12       Impact factor: 1.847

9.  Hyaluronic acid conjugates for topical treatment of skin cancer lesions.

Authors:  Vinu Krishnan; Kevin Peng; Apoorva Sarode; Supriya Prakash; Zongmin Zhao; Sergey K Filippov; Kristina Todorova; Brittney R Sell; Omar Lujano; Shirin Bakre; Anusha Pusuluri; Douglas Vogus; Kenneth Y Tsai; Anna Mandinova; Samir Mitragotri
Journal:  Sci Adv       Date:  2021-06-11       Impact factor: 14.136

10.  Chemosensitizing effect of podophyllotoxin acetate on topoisomerase inhibitors leads to synergistic enhancement of lung cancer cell apoptosis.

Authors:  Wan Gi Hong; Jeong Hyun Cho; Sang-Gu Hwang; Eunah Lee; Jaeseok Lee; Jong-Il Kim; Hong-Duck Um; Jong Kuk Park
Journal:  Int J Oncol       Date:  2016-04-01       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.